Autonomix Medical (NASDAQ:AMIX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Autonomix Medical (NASDAQ:AMIX) from a strong sell rating to a sell rating in a report issued on Sunday,Wall Street Zen reports.

A number of other brokerages have also weighed in on AMIX. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a research note on Tuesday, June 2nd. Weiss Ratings upgraded shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Autonomix Medical presently has a consensus rating of “Hold” and a consensus target price of $42.00.

Autonomix Medical Stock Performance

Shares of AMIX opened at $4.58 on Friday. The firm has a market capitalization of $4.45 million, a price-to-earnings ratio of -0.11 and a beta of -1.00. Autonomix Medical has a one year low of $2.44 and a one year high of $32.55. The stock’s fifty day moving average is $6.05 and its 200-day moving average is $7.38.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, topping the consensus estimate of ($6.40) by $1.38. Analysts forecast that Autonomix Medical will post -20.17 EPS for the current fiscal year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.